ProCE Banner Activity

Novel Strategies for Treating Double-Refractory CLL

Slideset

Download this slideset from a live symposium at ASH 2023 for expert perspectives on best practices in treating patients with CLL that has been previously treated with both a covalent BTK inhibitor and venetoclax-based therapy.

Released: December 07, 2023

Share

Faculty

Brian Hill

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene, Ltd., and Lilly.

AstraZeneca

BeiGene Ltd

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner